Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Slides:

Advertisements

Similar presentations

Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese.

Advertisements

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

HYPERTENSION in ADPKD Sabine Karam M.D.. Introduction  ADPKD is the most common life-threatening single-gene disease  It affects over 12 million people.

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Type 2 diabetes and high blood pressure How explosive is the cocktail?

Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint.

Hypertension Control and Progression of Renal Disease

CSM-1 Patients With and Without Obesity LSM Difference and 95% CI in BP (230, 231 Pooled) † Diastolic BP Overall (N = 1,191) Obese.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Relationship Between Magnitude of Proteinuria.

Antonio Coca, MD, PhD, FRCP, FESC

What should the Systolic BP treatment goal be in patients with CKD?

Nephrology Journal Club The SPRINT Trial Parker Gregg

Copyright © 2010 American Medical Association. All rights reserved.

Health and Human Services National Heart, Lung, and Blood Institute

Copyright © 2011 American Medical Association. All rights reserved.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Flowchart of participants

Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.

End point Patients >75 y with renal insufficiency

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?

Adjusted mortality risk

SAVE: Risk of total mortality associated with reduced kidney function

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Mean BP from initial visit to four years

Management of hypertension in patients with chronic kidney disease

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

PREMIER: Rate of hypertension at 18 months

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Hazard ratios (HR) for ESRD or death for 1-SD increase in systolic BP: Home recording vs clinic measurement BP measurement HR for each 1-SD increase.

Description of studies for pooled analyses

End point Net change with soy supplements vs control (95% CI) p

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Patient characteristics: American vs Canadian transplant patients

Krzysztof Narkiewicz et al. BTS 2016;1:

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Prehypertension: is it relevant for nephrologists?

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Volume 75, Issue 1, Pages (January 2009)

End point Valsartan Valsartan+HCTZ p

Comparison of nearest arm and leg blood pressure (BP) measurements.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95% CI <120/80 Reference — 120-129/80-84 1.62 1.27-2.07 130-139/85-89 1.98 1.55-2.52 140-159/90-99 2.59 2.07-3.25 160-179/100-109 3.86 3.00-4.96 180-209/110-119 3.88 2.82-5.34 >210/120 4.25 2.63-6.86 Hsu CY et al. Arch Intern Med 2005; 165:923-928.

Relative risk for incidence of ESRD with amlodipine and lisinopril vs diuretic in patients with mild or moderate to severe reductions in GFR at baseline Treatment group Relative risk 95% CI Diuretics Reference — Amlodipine Mild reduction in GFR 1.47 0.97-2.23 Moderate to severe reduction in GFR 0.92 0.68-1.24 Lisinopril Mild GFR reduction 1.34 0.87-2.06 0.98 0.73-1.31 Rahman M et al. Arch Intern Med 2005; 165:923-928.